Jpmorgan Chase & CO Harpoon Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$0.55 - $0.82 $40 - $59	-73 Reduced 5.08%	1,363 $0
Q1 2023 May 11, 2023	BUY	$0.65 - $1.37 $47 - $100	73 Added 5.36%	1,436 $1,000
Q4 2022 Feb 13, 2023	SELL	$0.6 - $1.41 $684 - $1,608	-1,141 Reduced 45.57%	1,363 $1,000
Q3 2022 Nov 14, 2022	BUY	$0.94 - $2.56 $670 - $1,825	713 Added 39.81%	2,504 $2,000
Q2 2022 Aug 11, 2022	SELL	$1.78 - $5.02 $353,433 - $996,761	-198,558 Reduced 99.11%	1,791 $3,000
Q1 2022 May 11, 2022	SELL	$3.54 - $8.08 $14,471 - $33,031	-4,088 Reduced 2.0%	200,349 $996,000
Q4 2021 Feb 10, 2022	SELL	$5.69 - $7.83 $56,046 - $77,125	-9,850 Reduced 4.6%	204,437 $1.54 Million
Q3 2021 Nov 12, 2021	BUY	$7.88 - $14.0 $1.69 Million - $3 Million	214,287 New	214,287 $1.69 Million

353K

Ticker HARP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,106,800
Description
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candi...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.